| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442459 | European Journal of Cancer | 2015 | 8 Pages |
Abstract
C- or P-based therapy did not increase the benefit of standard therapy or the BSC in RAS-wt/BRAF-mut CRC patients. These findings support BRAF mutation assessment before initiation of treatment with anti-EGFR monoclonal antibodies.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Filippo Pietrantonio, Fausto Petrelli, Andrea Coinu, Maria Di Bartolomeo, Karen Borgonovo, Claudia Maggi, Mary Cabiddu, Roberto Iacovelli, Ilaria Bossi, Veronica Lonati, Mara Ghilardi, Filippo de Braud, Sandro Barni,